slides · global inventory
Show Traction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 11,828
Current window 6,211-6,240
Pages 395
Rows per page 30
Slide function
6,211-6,240 of 11,828
14
Includes CAGR metrics for both revenue and EBITDA.Doximity | Investor Presentation Deck | 18 slides · Doximity
Pitch deck Investor relations 1 hit
06
Includes company origin, location, and a series of high-level KPIs.Dragonfly Energy | Investor Presentation Deck | 25 slides · Dragonfly Energy
Pitch deck Investor relations 1 hit
23
Dragonfly Energy | Investor Presentation Deck | 25 slidesDragonfly Energy | Investor Presentation Deck | 25 slides · Dragonfly Energy
Pitch deck Investor relations 1 hit
05
The slide uses a large background photo of a solar farm to provide context for the metrics.Eos Energy | Investor Presentation Deck | 16 slides · Eos Energy Enterprises, Inc.
Pitch deck Investor relations 1 hit
11
The slide uses a timeline framework to visualize the transition from facility construction to full production and subsequent transition to a new product generation.Eos Energy | Investor Presentation Deck | 16 slides · Eos Energy Enterprises, Inc.
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
15
Includes a detailed funding table and three key performance charts.Eos Energy | Investor Presentation Deck | 16 slides · Eos Energy Enterprises, Inc.
Pitch deck Investor relations Beat · Financials1 hit
16
The slide uses a structured list format to present three core pillars of progress.Eos Energy | Investor Presentation Deck | 16 slides · Eos Energy Enterprises, Inc.
Pitch deck Investor relations Beat · Financials1 hit
09
The chart shows AUV performance by center cohort, highlighting a maturity revenue of ~$1.1MM and the impact of COVID-19 in 2020.European Wax Center | Investor Presentation Deck | 25 slides · European Wax Center
Pitch deck Investor relations Beat · Business Model1 hit
10
The chart demonstrates a V-shaped recovery post-Q2 2020 and sustained growth above 2019 levels.European Wax Center | Investor Presentation Deck | 25 slides · European Wax Center
Pitch deck Investor relations Beat · Traction1 hit
11
Uses a causal chain/equation-like visual structure (A + B = C) to explain performance.European Wax Center | Investor Presentation Deck | 25 slides · European Wax Center
Pitch deck Investor relations Beat · Traction1 hit
19
Includes a table at the bottom of the charts showing net new centers, % SSS, and % growth.European Wax Center | Investor Presentation Deck | 25 slides · European Wax Center
Pitch deck Investor relations Beat · Financial Performance1 hit
20
Includes SSS (Same-Store Sales) metrics and margin percentages.European Wax Center | Investor Presentation Deck | 25 slides · European Wax Center
Pitch deck Investor relations Beat · Financial Performance1 hit
05
TPD = Targeted Protein Degradation; PK = Pharmacokinetics; PD = Pharmacodynamics; HS = Hidradenitis Suppurativa; AD = Atopic Dermatitis.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
12
The slide uses a split-screen comparison between healthy volunteer data and patient data.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
13
The slide uses a bulleted list structure to categorize findings between healthy volunteers and patients, concluding with a strategic partnership milestone.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
16
HS = Hidradenitis Suppurativa; AD = Atopic Dermatitis; HV = Healthy Volunteers; MAD = Multiple Ascending Dose; LLOQ = Lower Limit of Quantitation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
18
The slide compares cytokine inhibition efficacy in Healthy Subjects (MAD3), AD patients, and HS patients using two different stimulation methods (LPS and R848).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
19
The chart specifically visualizes IL-6 reduction over time, while the table summarizes max reduction across four markers.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
21
Data presented as mean percentage change with standard error bars; N=7.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
22
The chart tracks patient outcomes over time, showing a shift from severe/moderate to mild categories.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
24
The slide uses a comparison table to highlight efficacy metrics (EASI, Pruritus NRS) across different time points and benchmarks.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
25
Data compares 'All HS Patients' vs 'Moderate to Severe' subgroups. Includes error bars representing standard error of the mean or 80% confidence intervals.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
26
Data presented across three line charts comparing 'All HS Patients' vs 'Moderate to Severe' subgroups.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
27
The charts demonstrate a shift from higher severity scores (orange/red) to lower severity scores (blue/black) over time.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
36
The slide presents two charts: a tumor growth inhibition curve and a PK/PD correlation chart showing drug concentration vs. target degradation over time.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
39
Includes a disclaimer/footnote regarding patient population and MYD88 mutation status.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
43
The slide presents two distinct charts: a tumor volume growth curve and a PK/PD concentration-time profile.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
47
The slide presents clinical trial results for KT-333, comparing degradation percentages across three dose levels (DL1, DL2, DL3) over two cycles.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
48
Includes bar charts for SAA/CRP reduction, a longitudinal line chart for biomarker changes, and a scatter plot showing correlation between STAT3 and SOCS3 changes.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
49
DL1-3 refers to dose levels 1-3. PK = Pharmacokinetics, PD = Pharmacodynamics, DLT = Dose-Limiting Toxicity, SAE = Serious Adverse Event.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit